Metoclopramid Arena

Metoclopramide, the active ingredient in Metoclopramid Arena, is a dopamine D2 receptor antagonist presented as an oral dosage form for oral use. It treats nausea and vomiting and facilitates gastric emptying in adults.

GNH USA supplies Metoclopramid Arena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide is used to manage conditions that involve impaired gastrointestinal motility or nausea pathways. - Nausea and vomiting (including postoperative and chemotherapy‑induced): reduces the frequency and severity of nausea and vomiting. - Gastroparesis: enhances gastric emptying and improves related symptoms. - Gastroesophageal reflux disease (GERD): promotes gastric motility to lessen reflux episodes.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or akathisia - Diarrhea - Constipation - Headache

Serious or Rare Side Effects: - Tardive dyskinesia (involuntary movements) - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Seizures - Anaphylactic or severe allergic reactions - Cardiac arrhythmias, including QT prolongation

Before prescribing Metoclopramid Arena, clinicians should consider several safety measures. - Assess renal and hepatic function: adjust use in impairment. - Monitor for extrapyramidal symptoms: watch for tremor, rigidity, or abnormal movements. - Evaluate mental health status: be alert for depression or suicidal ideation. - Use caution in patients with gastrointestinal obstruction or perforation. - Avoid in individuals with known hypersensitivity to metoclopramide. - Store at ambient temperature: keep in the original packaging, protect from moisture.

Metoclopramide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Anticholinergic agents: may reduce pro‑kinetic efficacy. - MAO inhibitors: increased risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation. - Strong CYP3A4 inhibitors: elevate metoclopramide plasma levels. - QT‑prolonging drugs: heightened arrhythmia risk.

Moderate Interactions (Monitor Closely): - Opioids: may exacerbate nausea. - Other dopamine antagonists: additive extrapyramidal effects. - Selective serotonin reuptake inhibitors (SSRIs): potential serotonin syndrome. - Diuretics: possible electrolyte disturbances affecting cardiac safety.